• Je něco špatně v tomto záznamu ?

Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial

Z. Bawa, D. McCartney, M. Bedoya-Pérez, NS. Lau, R. Fox, H. MacDougall, IS. McGregor

. 2024 ; 14 (3) : e082927. [pub] 20240325

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu protokol klinické studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006662

INTRODUCTION: The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products. METHODS: We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality (VR) challenges (tasks) designed to induce transient stress and motion sickness: (a) a 15 min 'Public Speaking' task; (b) a 5 min 'Walk the Plank' task (above a sheer drop); and (c) a 5 min 'Rollercoaster Ride' task. The primary outcomes will be self-reported stress and nausea measured on 100 mm Visual Analogue Scales. Secondary outcomes will include salivary cortisol concentrations, skin conductance, heart rate and vomiting episodes (if any). Statistical analyses will test the hypothesis that CBD reduces nausea and attenuates subjective, endocrine and physiological responses to stress compared with placebo. This study will indicate whether low-dose oral CBD has positive effects in reducing acute psychosocial stress, situational anxiety, motion sickness and cybersickness. ETHICS AND DISSEMINATION: The University of Sydney Human Research Ethics Committee has granted approval (2023/307, version 1.6, 16 February 2024). Study findings will be disseminated in a peer-reviewed journal and at academic conferences. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12623000872639).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006662
003      
CZ-PrNML
005      
20240423155431.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2023-082927 $2 doi
035    __
$a (PubMed)38531572
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bawa, Zeeta $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia $1 https://orcid.org/0000000223467557
245    10
$a Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial / $c Z. Bawa, D. McCartney, M. Bedoya-Pérez, NS. Lau, R. Fox, H. MacDougall, IS. McGregor
520    9_
$a INTRODUCTION: The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of CBD. Relatively few studies have investigated the efficacy of lower (<300 mg) oral doses, typical of those available in over-the-counter CBD products. METHODS: We present a protocol for a randomised, double-blind, placebo-controlled, parallel-group clinical trial investigating the effects of a low oral dose (150 mg) of CBD on acute psychosocial stress, situational anxiety, motion sickness and cybersickness in healthy individuals. Participants (n=74) will receive 150 mg of CBD or a matched placebo 90 min before completing three virtual reality (VR) challenges (tasks) designed to induce transient stress and motion sickness: (a) a 15 min 'Public Speaking' task; (b) a 5 min 'Walk the Plank' task (above a sheer drop); and (c) a 5 min 'Rollercoaster Ride' task. The primary outcomes will be self-reported stress and nausea measured on 100 mm Visual Analogue Scales. Secondary outcomes will include salivary cortisol concentrations, skin conductance, heart rate and vomiting episodes (if any). Statistical analyses will test the hypothesis that CBD reduces nausea and attenuates subjective, endocrine and physiological responses to stress compared with placebo. This study will indicate whether low-dose oral CBD has positive effects in reducing acute psychosocial stress, situational anxiety, motion sickness and cybersickness. ETHICS AND DISSEMINATION: The University of Sydney Human Research Ethics Committee has granted approval (2023/307, version 1.6, 16 February 2024). Study findings will be disseminated in a peer-reviewed journal and at academic conferences. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12623000872639).
650    _2
$a lidé $7 D006801
650    12
$a kanabidiol $x terapeutické užití $7 D002185
650    _2
$a úzkost $x farmakoterapie $7 D001007
650    _2
$a nauzea $x farmakoterapie $7 D009325
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a kinetózy $x farmakoterapie $7 D009041
650    _2
$a psychický stres $7 D013315
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
651    _2
$a Austrálie $7 D001315
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
700    1_
$a McCartney, Danielle $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia
700    1_
$a Bedoya-Pérez, Miguel $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia
700    1_
$a Lau, Namson S $u The Boden Initiative, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
700    1_
$a Fox, Richard $u Yellow Dog Man Studios s.r.o, Ostrava-jih-Zábřeh, Czechia
700    1_
$a MacDougall, Hamish $u RPA Institute of Academic Surgery, Sydney Local Health District, Sydney, New South Wales, Australia
700    1_
$a McGregor, Iain S $u The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia iain.mcgregor@sydney.edu.au $u The Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia $u School of Psychology, The University of Sydney, Sydney, New South Wales, Australia $1 https://orcid.org/0000000293077159
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 14, č. 3 (2024), s. e082927
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38531572 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155428 $b ABA008
999    __
$a ok $b bmc $g 2080963 $s 1216429
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 3 $d e082927 $e 20240325 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace